Elisidepsin

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameElisidepsin
Drug Alias Name依利地新elisidepsinum艾利迪星elisidepsinaIrvalec +[7] 
ClassificationNatural product/ExtractSmall molecules > Synthetic peptide
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharma Mar Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharma Mar Sa
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A